High-dose PPI
Phase 3Small molecule
High-dose PPI is one of 73 small molecule programs targeting Chronic Cough. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
66 competitors in Vascular Disease
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Repatha
AmgenApproved
Precose
BayerApproved
Letairis
GileadApproved
Colcrys
Alnylam PharmaceuticalsApproved
Zesly
MMezzion Pharma Co. Ltd
Approved
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Andriol
AAuxilium
Approved
Donepezil Hydrochloride
EisaiApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Cough1 trial
Vascular Disease1 trial
Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation
Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT01051388·280 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for High-dose PPI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- YYonsei University